201 related articles for article (PubMed ID: 3108098)
1. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
[No Abstract] [Full Text] [Related]
2. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
[No Abstract] [Full Text] [Related]
3. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
Jehn U; Göldel N; Vehling-Kaiser U
Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
[TBL] [Abstract][Full Text] [Related]
4. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
5. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
7. [Cytarabine].
Ota K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2983-7. PubMed ID: 3478003
[TBL] [Abstract][Full Text] [Related]
8. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
[No Abstract] [Full Text] [Related]
9. [Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine].
Pignon B; Blaise AM; Boilletot A; Herbrecht R; Rozenbaum A; Flesch M; Audhuy B; Barats JC
Nouv Rev Fr Hematol (1978); 1986; 28(6):345-8. PubMed ID: 3470706
[TBL] [Abstract][Full Text] [Related]
10. Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy.
Sticklin LA; Dubbelde K; Larson E
Oncol Nurs Forum; 1989; 16(3):365-9. PubMed ID: 2734216
[TBL] [Abstract][Full Text] [Related]
11. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
12. Low dose Ara-C for patients with myelodysplastic syndromes.
Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
[TBL] [Abstract][Full Text] [Related]
13. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
14. [A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
Maruta A; Miyashita H; Kodama F; Harano H; Kanamori H; Takahashi K; Noguchi T; Matsuzaki M; Ogawa K; Motomura S
Rinsho Ketsueki; 1988 Jan; 29(1):8-13. PubMed ID: 3385938
[No Abstract] [Full Text] [Related]
15. Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
el-Mangoush M; Singh NK
J Assoc Physicians India; 1992 Jul; 40(7):452-4. PubMed ID: 1484026
[TBL] [Abstract][Full Text] [Related]
16. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
[TBL] [Abstract][Full Text] [Related]
17. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
Bolwell BJ; Cassileth PA; Gale RP
Leukemia; 1987 Aug; 1(8):575-9. PubMed ID: 3312846
[TBL] [Abstract][Full Text] [Related]
18. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
[TBL] [Abstract][Full Text] [Related]
19. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
20. Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.
Pluta A; Kowalewski J; Kurowska M; Spiewak H; Hus M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):787-91. PubMed ID: 1713883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
